The SACRIX system is a minimally invasive sacroiliac joint stabilization device that provides structural support to the SI joint. Unlike full fusion procedures, SACRIX offers a less-invasive approach using allograft-based implants that promote natural bone healing and joint stabilization while preserving some physiologic motion.
Under fluoroscopic guidance, the SACRIX allograft implant is placed across the sacroiliac joint through a small percutaneous approach. The implant bridges the joint, providing immediate mechanical stabilization while the allograft material promotes biological incorporation.
Recovery is typically faster than traditional SI joint fusion. Activity restrictions last 4-6 weeks to allow implant incorporation. Clinical outcomes show sustained pain relief and functional improvement.
The SACRIX system uses a corticocancellous allograft implant that is precisely shaped to fit across the SI joint. The allograft material provides immediate structural support while serving as a scaffold for new bone growth. Over time, the patient's own bone cells infiltrate the allograft, incorporating it into the native bone structure.
Unlike metallic fusion implants, the SACRIX allograft is biologically resorbed and replaced by the patient's own bone tissue over time, creating a natural biologic stabilization without permanent hardware.
The procedure is performed under conscious sedation or general anesthesia. A small incision is made in the buttock, and the allograft implant is placed across the SI joint under fluoroscopic guidance. The procedure typically takes 30-45 minutes.
Patients may notice immediate improvement in SI joint stability and reduction in pain due to the mechanical stabilization provided by the implant.
Activity restrictions for 4-6 weeks include limited walking with a walker or crutches for the first 2-3 weeks, followed by gradual progression to full weight-bearing. Sitting for prolonged periods should be avoided during the initial recovery phase.
A structured physical therapy program focuses on core stabilization, gait training, and gradual return to normal activities. Most patients return to sedentary work within 2-4 weeks.
SACRIX is indicated for patients with SI joint dysfunction who have failed conservative management. Contraindications include active infection, severe osteoporosis, known allergy to allograft tissue, and conditions that would impair bone healing.
Reducing Pain. Improving Function. Enhancing Quality of Life.
We specialize in advanced pain management solutions, offering minimally invasive treatments to help patients live pain-free and improve their quality of life.